The efficacy of T-DXd in patients with HER2-positive/low breast cancer is currently being evaluated in several clinical trials, such as DESTINY-Breast 05 through DESTINY-Breast 12 [14]. The gene discussed is ERBB2; the disease is breast carcinoma.